|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 6
Zeitschriftenartikel
Boukovala, Myrto; Modest, Dominik Paul; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Peveling Genannt Reddemann, C.; Graeven, Ullrich 
ORCID: https://orcid.org/0000-0001-6082-7710; Schuch, Gunter ORCID: https://orcid.org/0000-0001-7503-457X; Schwaner, Ingo ORCID: https://orcid.org/0000-0001-8865-7282; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Neumann, Jens; Jung, Andreas; Held, Swantje ORCID: https://orcid.org/0000-0002-1344-9056; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Michl, Marlies ORCID: https://orcid.org/0000-0002-4198-3627
(2024):
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
In: ESMO Open, Bd. 9, Nr. 5, 103374
[PDF, 725kB]
ORCID: https://orcid.org/0000-0001-6082-7710; Schuch, Gunter ORCID: https://orcid.org/0000-0001-7503-457X; Schwaner, Ingo ORCID: https://orcid.org/0000-0001-8865-7282; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Neumann, Jens; Jung, Andreas; Held, Swantje ORCID: https://orcid.org/0000-0002-1344-9056; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Michl, Marlies ORCID: https://orcid.org/0000-0002-4198-3627
(2024):
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
In: ESMO Open, Bd. 9, Nr. 5, 103374
[PDF, 725kB]
Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Heinrich, Kathrin; Held, Swantje; Stahler, Arndt; Alig, Annabel Helga Sophie; Jelas, Ivan; Einem, Jobst C. von; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P.
(2022):
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
In: Frontiers in Oncology, Bd. 12, 751453
Heinrich, Kathrin; Modest, Dominik P.; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Graeven, Ullrich; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Giessen-Jung, Clemens; Stahler, Arndt; Michl, Marlies; Held, Swantje; Jung, Andreas; Kirchner, Thomas; Stintzing, Sebastian und Heinemann, Volker
(2021):
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
In: European Journal of Cancer, Bd. 147: S. 128-139
Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Schwaner, Ingo; Stahler, Arndt; Heinrich, Kathrin; Jung, Andreas; Held, Swantje; von Einem, Jobst C.; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P.
(2020):
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
In: European Journal of Cancer, Bd. 137: S. 81-92
Modest, Dominik Paul; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Reddemann, Christina Peveling Genannt; Graeven, Ullrich; Schuch, Gunter; Schwaner, Ingo; Stahler, Arndt; Jung, Andreas; Kirchner, Thomas; Held, Swantje; Stintzing, Sebastian; Giessen-Jung, Clemens und Heinemann, Volker
(2019):
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled StudyXELAVIRI (AIO KRK0110).
In: Journal of Clinical Oncology, Bd. 37, Nr. 1
Giessen, Clemens; Fischer von Weikersthal, Ludwig; Hinke, Axel; Stintzing, Sebastian; Kullmann, Frank; Vehling-Kaiser, Ursula; Mayerle, Julia; Bangerter, Markus; Denzlinger, Claudio; Sieber, Markus; Teschendorf, Christian; Freiberg-Richter, Jens; Schulz, Christoph; Modest, Dominik Paul; Moosmann, Nicolas; Aubele, Philipp und Heinemann, Volker
(2011):
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial.
In: BMC Cancer
11:367
[PDF, 533kB]